{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:10:54Z","timestamp":1790716254251,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Hematology"],"published-print":{"date-parts":[[2007,7,1]]},"DOI":"10.1532\/ijh97.07028","type":"journal-article","created":{"date-parts":[[2007,8,14]],"date-time":"2007-08-14T19:14:42Z","timestamp":1187118882000},"page":"49-57","source":"Crossref","is-referenced-by-count":46,"title":["Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy"],"prefix":"10.1007","volume":"86","author":[{"given":"Akihiro","family":"Tomita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Hiraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Cheson BD. Monoclonal antibody therapy for B-cell malignancies. Semin Oncol.<\/i> 2006;33:S2-S14.","DOI":"10.1053\/j.seminoncol.2006.01.024"},{"key":"E00002","unstructured":"Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer.<\/i> 2006;6:714-727."},{"key":"E00003","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med.<\/i> 2002;346:235-242."},{"key":"E00004","unstructured":"van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin's lymphoma both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood.<\/i> 2006;108:3295-3301."},{"key":"E00005","unstructured":"Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol.<\/i> 2006;24:3121-3127."},{"key":"E00006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol.<\/i> 2006;7:379-391."},{"key":"E00007","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood.<\/i> 2005;106:3725-3732."},{"key":"E00008","unstructured":"Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol.<\/i> 2004;22:4711-4716."},{"key":"E00009","unstructured":"Alvaro-Naranjo T, Jaen-Martinez J, Guma-Padro J, Bosch-Princep R, Salvado-Usach MT. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Ann Hematol.<\/i> 2003;82:585-588."},{"key":"E00010","doi-asserted-by":"crossref","unstructured":"Terui Y, Sakurai T, Mishima Y, et al. Identification of CD20 mutations in malignant lymphoma: can they be predictors of response to rituximab? [abstract]. Blood.<\/i> 2005;106:88a. Abstract 288.","DOI":"10.1182\/blood.V106.11.288.288"},{"key":"E00011","unstructured":"Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res.<\/i> 1999;5:611-615."},{"key":"E00012","unstructured":"Kinoshita T, Nagai H, Murate T, Saito H. CD20-negative relapse in B-cell lymphoma after treatment with rituximab. J Clin Oncol.<\/i> 1998;16:3916."},{"key":"E00013","doi-asserted-by":"crossref","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene.<\/i> 2003;22:7359-7368.","DOI":"10.1038\/sj.onc.1206939"},{"key":"E00014","unstructured":"Ninomiya M, Abe A, Yokozawa T, et al. Establishment of a myeloid leukemia cell line, TRL-01, with MLL-ENL<\/i> fusion gene. Cancer Genet Cytogenet.<\/i> 2006;169:1-11."},{"key":"E00015","unstructured":"Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, van Dongen JJ. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol.<\/i> 1990;136:1215-1222."},{"key":"E00016","unstructured":"Atsumi A, Tomita A, Kiyoi H, Naoe T. Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RAR\u03b1 as a component of the N-CoR co-repressor complex to repress transcription in vivo. Biochem Biophys Res Commun.<\/i> 2006;345:1471-1480."},{"key":"E00017","unstructured":"Kiyoi H, Naoe T, Kitamura K, Yamauchi T, Ichihashi T, Ohno R. Disappearance of minimal residual lymphoblastic leukemia cells 6 months after allogeneic bone marrow transplantation without GVHD. Bone Marrow Transplant.<\/i> 1991;8:59-62."},{"key":"E00018","unstructured":"Gribben JG, Freedman A, Woo SD, et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood.<\/i> 1991;78:3275-3280."},{"key":"E00019","unstructured":"Ravetch JV, Siebenlist U, Korsmeyer S, Waldmann T, Leder P. Structure of the human immunoglobulin mu locus: characterization of embryonic and rearranged J and D genes. Cell.<\/i> 1981;27:583-591."},{"key":"E00020","unstructured":"Tomita A, Buchholz DR, Shi YB. Recruitment of N-CoR\/SMRT-TBLR1 corepressor complex by unliganded thyroid hormone receptor for gene repression during frog development. Mol Cell Biol.<\/i> 2004;24:3337-3346."},{"key":"E00021","unstructured":"Tomita A, Buchholz DR, Obata K, Shi YB. Fusion protein of retinoic acid receptor \u03b1 with promyelocytic leukemia protein or promyelocytic leukemia zinc finger protein recruits N-CoR-TBLR1 corepressor complex to repress transcription in vivo. J Biol Chem.<\/i> 2003;278:30788-30795."},{"key":"E00022","unstructured":"Crescenzi M, Seto M, Herzig GP, Weiss PD, Griffith RC, Korsmeyer SJ. Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci U S A.<\/i> 1988;85:4869-4873."},{"key":"E00023","unstructured":"Kosugi H, Towatari M, Hatano S, et al. Histone deacetylase inhibitors are the potent inducer\/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia.<\/i> 1999;13:1316-1324."},{"key":"E00024","unstructured":"Hsia SC, Tomita A, Obata K, Paul B, Buchholz D, Shi YB. Role of chromatin disruption and histone acetylation in thyroid hormone receptor action: implications in the regulation of HIV-1 LTR. Histol Histopathol.<\/i> 2003;18:323-331."},{"key":"E00025","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood.<\/i> 1997;90:2188-2195."},{"key":"E00026","unstructured":"Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol.<\/i> 1997;15:3266-3274."},{"key":"E00027","unstructured":"Pegoraro L, Palumbo A, Erikson J, et al. A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci U S A.<\/i> 1984;81:7166-7170."},{"key":"E00028","unstructured":"Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature.<\/i> 2004;429:457-463."},{"key":"E00029","unstructured":"Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood.<\/i> 2006;108:1975-1978."},{"key":"E00030","unstructured":"Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol.<\/i> 2005;1:143-145."},{"key":"E00031","unstructured":"Kiyoi H, Naoe T. Immunoglobulin variable region structure and B-cell malignancies. Int J Hematol.<\/i> 2001;73:47-53."}],"container-title":["International Journal of Hematology"],"original-title":[],"link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1532\/IJH97.07028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T21:26:03Z","timestamp":1587849963000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1532\/IJH97.07028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,7,1]]}},"alternative-id":["A0P230247M851HJ6"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.07028","relation":{},"ISSN":["0925-5710"],"issn-type":[{"value":"0925-5710","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7,1]]}}}